Nasdaq:TNGX
Tango Therapeutics, Inc.
A clinical-stage biopharma firm advancing a diverse pipeline of novel therapies via its unique Tango Platform technology.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted to Tango Therapeutics for its innovative platform technology and a robust pipeline of novel therapies with potential blockbuster value. The company's strong liquidity position allows it to navigate the high-risk clinical development phase without immediate pressure to sell assets or issue equity. Successful commercialization of current assets could provide a significant turnaround story from its current loss-making status.
Bear Case
The widening net loss and negative operating cash flow present a critical challenge that requires successful asset monetization or major financing events to resolve. The absence of revenue growth sufficient to cover the high burn rate creates uncertainty regarding the company's long-term sustainability. Regulatory hurdles and clinical trial failures for its drug candidates could severely impact its valuation and ability to generate returns.
About Tango Therapeutics, Inc.
Tango Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious diseases using its proprietary Tango Platform. The company operates primarily in the United States market, leveraging asset acquisition to advance multiple drug candidates through clinical development while maintaining a lean cost structure.
Analysis
Management Discussion
Despite a slight increase in revenue from $24.9M in 2022 to $42.1M in 2024, the company's net losses have widened to -$130.3M, reflecting heavy investment in research and development totaling $143.9M. The cash flow from operations of -$131.5M was partially offset by significant financing inflows, resulting in an ending cash balance that remains healthy at $72.1M.
Industry Overview
The biopharmaceutical industry is characterized by high barriers to entry, intense competition, and significant regulatory oversight required for drug approval. Companies in this sector often operate with negative net income initially as they invest heavily in research before achieving commercialization milestones. Market dynamics favor firms with proprietary technologies that can differentiate their products and secure exclusive licensing deals.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $24.9M | $36.5M | $42.1M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $24.9M | $36.5M | $42.1M |
| Operating Expenses | $135.9M | $150.7M | $187.7M |
| Operating Income | $-111.1M | $-114.2M | $-145.6M |
| R&D | $105.9M | $115.2M | $143.9M |
| G&A | $30.0M | $35.5M | $43.7M |
| Stock-Based Comp | $14.2M | $19.1M | $28.9M |
| Depreciation | $1.6M | $2.4M | $2.5M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $2.9M | $12.6M | $15.5M |
| Pre-Tax Income | $-108.1M | $-101.6M | $-130.1M |
| Income Tax | $54.0K | $134.0K | $208.0K |
| Continuing Ops | $-108.2M | $-101.7M | $-130.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-108.2M | $-101.7M | $-130.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-108.2M | $-101.7M | $-130.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $375.3M | $346.5M | $266.3M |
| Cash & Equivalents | $60.0M | $66.4M | $69.5M |
| Marketable Securities | $306.2M | $270.5M | $188.4M |
| Accounts Receivable | $2.0M | — | — |
| Prepaid Expenses | $6.6M | $8.8M | $8.4M |
| Other Current Assets | $567.0K | $856.0K | $0 |
| Long-Term Assets | $61.2M | $56.0M | $50.1M |
| PP&E (Net) | $10.9M | $9.9M | $8.1M |
| Operating Leases | $46.9M | $43.5M | $39.5M |
| Other LT Assets | $3.4M | $2.6M | $2.6M |
| Total Assets | $436.5M | $402.6M | $316.5M |
| Current Liabilities | $55.5M | $45.9M | $38.2M |
| Accounts Payable | $4.5M | $2.8M | $1.6M |
| Current Leases | $1.8M | $2.1M | $2.5M |
| Deferred Revenue | $31.8M | $25.7M | $17.6M |
| Other Current Liab | $17.5M | $15.4M | $16.5M |
| Long-Term Liabilities | $131.4M | $103.5M | $78.8M |
| LT Operating Leases | $39.4M | $36.8M | $34.0M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $187.0M | $149.5M | $117.0M |
| Shareholders' Equity | $249.5M | $253.1M | $199.5M |
| Paid-In Capital | $522.6M | $624.1M | $700.6M |
| Retained Earnings | $-269.5M | $-371.3M | $-501.6M |
| AOCI | $-3.7M | $186.0K | $336.0K |
| Total L&E | $436.5M | $402.6M | $316.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-108.2M | $-101.7M | $-130.3M |
| Non-Cash Adjustments | $12.9M | $16.7M | $30.4M |
| Working Capital Changes | $-13.8M | $-33.0M | $-31.6M |
| Cash from Operations | $-109.1M | $-118.0M | $-131.5M |
| Capital Expenditures | $7.7M | $1.5M | $754.0K |
| Cash from Investing | $26.4M | $41.4M | $86.1M |
| Cash from Financing | $1.6M | $82.4M | $47.7M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-81.1M | $5.8M | $2.3M |
| Beginning Cash | $145.0M | $64.0M | $69.8M |
| Ending Cash | $64.0M | $69.8M | $72.1M |
Frequently Asked Questions
How does Tango Therapeutics, Inc. make money?
The company derives revenue from licensing agreements and commercial sales associated with its drug candidates, supported by substantial cash reserves in marketable securities. Financials indicate significant investment in research and development alongside general and administrative expenses typical of late-stage clinical biopharmaceutical operations.
What are the main risks for TNGX?
The company faces significant financial risk due to substantial net losses and a retained earnings deficit that could impact solvency if cash flows do not improve. As a clinical-stage entity, there is no guarantee that current drug candidates will successfully complete trials or receive regulatory approval. High operating expenses driven by R&D and general administration pose a threat to liquidity if revenue growth does not outpace burn rate.
What is TNGX's competitive advantage?
Tango Therapeutics possesses a differentiated proprietary platform that accelerates the discovery and development of novel therapies. The company benefits from a diverse portfolio of drug candidates at various stages, reducing reliance on any single asset. Strong balance sheet liquidity provides flexibility to fund high-cost research programs without immediate dilution.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.